Improving Care for Patients with Craniopharyngioma

Dear Colleagues, 

Craniopharyngioma is a rare low-grade intracranial tumor located in the hypothalamic–pituitary axis. The tumor has an overall annual incidence of 0.13–0.18 per 100,000 persons in the United States, accounting for 5–15% of intracranial tumors in children. Craniopharyngioma is most often diagnosed in childhood (5–14 years) and later adulthood (50–74 years). The tumor location places the patient at risk for significant sequelae and is most severe in those with grade 2 hypothalamic involvement prior to surgical resection. These sequelae result in long-term hormone deficiency, neurocognitive impairment, sleep disturbance, hypothalamic obesity, and decreased health-related quality of life. This Special Issue will describe treatment modalities and supportive care interventions addressing subsequent health-related issues. 

As you know, craniopharyngioma is a rare tumor, with the intent to decrease the morbidity associated with tumor location, surgical resection, and cranial radiotherapy. We are co-editing a Special Issue of Cancers (Impact Factor = 6.575) focused on treatment and supportive interventions for craniopharyngioma morbidities. We are pleased to invite you to contribute an article on this topic. We are specifically seeking papers related to treatment and assessment of and/or intervention for sequelae of craniopharyngioma, including long-term hormone deficiency, neurocognitive impairment, sleep disturbance, hypothalamic obesity, psychosocial functioning, and/or health-related quality of life. 

This Special Issue aims to describe treatment and supportive care needs and interventions to address craniopharyngioma-related morbidity. In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Dr. Belinda N. Mandrell
Dr. Valerie McLaughlin Crabtree
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.